Latest Clinical News

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (02-7-2018)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people... Continue Reading

Guidelines for Human Papilloma Virus Testing in Head and Neck Carcinomas (02-6-2018)

CancerConnect News:  The Centers for Disease Control and Prevention estimates that in the United States, there are more than 16,000 individuals diagnosed with Human Papilloma Virus (HPV)-positive OroPharyngeal Squamous Cell Carcinoma (OPSCC) each year... Continue Reading

FDA Approves Lutathera for Treatment for Certain Digestive Tract Cancers (02-6-2018)

CancerConnect News: The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors... Continue Reading

Breast Cancer Treatments May Increase Risk of Heart Disease (02-5-2018)

American Heart Association Scientific Statement Statement Highlights: Some breast cancer therapies can damage the heart and healthcare providers should carefully monitor breast cancer treatment effects on the heart. Breast cancer survivors, especially... Continue Reading

PD-1 Antibody Cemiplimab Appears Promising for Treatment of Squamous Cell Carcinoma of the Skin (02-2-2018)

Cemiplimab an investigational human antibody targeting PD-1 (programmed cell death protein 1), is yet another “checkpoint inhibitor” that was evaluated in 82 patients with advanced cutaneous squamous cell carcinoma (CSCC).  Early trial results suggest... Continue Reading

E-cigarettes May Help Adults Switch From Cigarettes but Encourage Smoking in Teens (02-1-2018)

By AMERICAN HEART ASSOCIATION NEWS CancerConnect News: E-cigarettes can be highly addictive, and kids who use them are more likely to start smoking regular cigarettes, concluded a panel of public health experts. A report released this week by the National... Continue Reading

Depressive Symptoms Linked to Shorter Survival in Patients with Head and Neck Cancer (01-31-2018)

CancerConnect News:  In a study of patients with head and neck cancer, even mild depressive symptoms were associated with poorer overall survival according to a team of doctors from the University of Louisville who published their findings in Cancer... Continue Reading

U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia (01-31-2018)

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL)... Continue Reading

Uterine Cancer: The Next Immunotherapy Frontier? (01-30-2018)

CancerConnect News: All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult... Continue Reading

Roswell Park Research Identifies Link between Smoking, Sex Hormones and Lung Cancer (01-29-2018)

CancerConnect News:  The risk of developing non-small cell lung cancer (NSCLC) is higher for women and smokers according to the results of a recent study published by a team of doctors led by Christine Ambrosone, PhD, Chair of Cancer Prevention and Control... Continue Reading

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma (01-25-2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential... Continue Reading

FDA Broadens Gilotrif Indication to Previously Untreated, Metastatic NSCLC with Other Non-Resistant EGFR Mutations (01-24-2018)

CancerConnect News: The Food and Drug Administration (FDA) has granted approval to Gilotrif®  (afatinib) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant... Continue Reading

« Previous PageNext Page »